Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 117Carcinoma, Non-Small-Cell Lung 102Carcinoma, Renal Cell 70Colorectal Neoplasms 46Neoplasm Metastasis 41Squamous Cell Carcinoma of Head and Neck 39Carcinoma, Hepatocellular 38Neoplasms 36Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Hodgkin Disease 20Carcinoma, Transitional Cell 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 17Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Triple Negative Breast Neoplasms 14Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 15Radiotherapy 14Specimen Handling 13Radiation 9Biopsy 5pembrolizumab 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Bevacizumab 4vorasidenib 3trametinib 3Surgical Procedures, Operative 3Spinal Puncture 3tovorafenib 2dabrafenib 2Restraint, Physical 2Leukapheresis 2Ipilimumab 2Genetic Therapy 2Fluorodeoxyglucose F18 2Eflornithine 2Craniotomy 2Carboplatin 214-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 2vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tozuleristide 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Astrocytoma × Nivolumab × 1 year × Clear all
NCT04145115 2026-05-29

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled
CNS

Astrocytoma, Glioblastoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT07031765 2025-12-18

Peds CHAMP1ON

University of Florida

Phase 1 Active not recruiting
12 enrolled
CNS

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma

NCT06896110 2025-06-26

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

University of Iowa

Phase 1 Enrolling by invitation
34 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡